|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||83.58 - 84.17|
|52 Week Range||65.66 - 89.09|
|PE Ratio (TTM)||36.36|
|Earnings Date||Jan 31, 2018|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||91.90|
Eli Lilly, one of the biggest makers of insulin, has been planning a risky new business venture: making the high-tech devices that deliver insulin to diabetes patients.
In November 2017, the FDA approved Merck’s (MRK) Prevymis (letermovir) for the prevention of CMV (cytomegalovirus) infection and disease in adult CMV-seropositive recipients of allogeneic hematopoietic ...
Lilly (LLY) enters into a development agreement with DexCom to integrate the latter's continuous glucose monitoring into its Connected Diabetes Ecosystem.
Silver Spring-based United Therapeutics Corp. will have six more months of commercial exclusivity for Adcirca, one of its leading pulmonary arterial hypertension drugs set to lose part of its patent protection Tuesday. Just a day before the drug's patent was set to expire, the Food and Drug Administration said it would extend pediatric exclusivity to United Therapeutics (UTHR) through May 21 for its Adcirca tablets, which made up nearly a quarter of the local biotech's revenue last year. The FDA's decision, based on study results submitted by Eli Lilly and Co. (LLY), will delay any cheaper, generic version of Adcirca from being approved in the next six months.
DexCom, Inc. , the leader in continuous glucose monitoring for people with diabetes, today announced a development agreement with Eli Lilly and Company to include Dexcom CGM into Lilly’s Connected Diabetes Ecosystem.
United Therapeutics' PAH drug, Adcirca has been granted six months pediatric exclusivity. This will delay generic competition for the drug for an additional six months.
WASHINGTON (AP) — Newly disclosed financial records show that President Donald Trump's nominee to become Health and Human Services secretary reaped big earnings during his tenure as a top pharmaceutical executive.
INDIANAPOLIS, Nov. 20, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) will announce its financial guidance for 2018 on Wednesday, December 13, 2017. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial guidance. The conference call will begin at 10 a.m. Eastern time.
Celldex (CLDX) enrolled the first patient in a phase II study on pipeline candidate, CDX-3379, to evaluate it in advanced head and neck squamous cell carcinoma patients.
INDIANAPOLIS , Nov. 17, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference on Thursday, November 30, 2017 . Dan Skovronsky ...
In 3Q17, AstraZeneca reported EPS of $0.56 on revenues of $6.2 billion compared to estimates of $0.71 for EPS on revenues of $6 billion.
A securities filing made Tuesday by Express Scripts Holdings (ESRX) disclosed two large lawsuits that claim its subsidiary United Biosource helped drugmakers market their products in violation of antitrust and anti-kickback laws. The allegations in those suits touch on issues that Barron’s covered in a 2015 story that described how UBC’s contracts to promote drugmakers’ high-priced products seemed to conflict with the mission of its pharmacy benefit management parent: that is, to keep a lid on America’s drug bills (“Express Scripts Unit’s Connection to High Priced Specialty Drugs,” November 21, 2015). Other companies also named as defendants in the two suits were Eli Lilly & Co. (LLY) and Mallinckrodt PLC (MNK), as well as the Covance unit of Laboratory Corp. of America Holdings (LH).
Dividend stock investing is inherently a long-term enterprise. After all, companies only pay their investors dividends once a quarter and dividend yields are calculated on an annualized basis. The real power of dividend stocks comes from the power to deliver consistent returns and growing payouts over the very long term — not several years, but more like several decades.
Worry whether drug pricing will return to the forefront in Washington, D.C. is increasing following Donald Trump's nomination of a drug-industry insider as his next Department of Health and Human Services secretary.
In 3Q17, Novartis’s Cosentyx generated revenues of $556 million, which reflected a whopping 85% growth YoY (year-over-year) and ~13% growth QoQ.
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Eli Lilly & Co. with the following peers – Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Bristol-Myers Squibb Company, Sanofi Sponsored ADR, GlaxoSmithKline plc Sponsored ADR, AbbVie, Inc., Roche Holding Ltd Genusssch., Amgen Inc. and Novartis AG Sponsored ADR (JNJ-US, MRK-US, PFE-US, BMY-US, ... Read more (Read more...)
Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.
President Trump tweeted that his nominee for Secretary of Health and Human Services will be a “star” for his ability to lower drug prices, but during Alex Azar’s tenure at Eli Lilly & Co. prices rose dramatically ...
Dexcom CEO Kevin Sayer on how his company is working with Fitbit in order to help people with diabetes monitor their glucose levels.